CardiologyOnline.net

Cardiology Xagena

Increased risk of ventricular tachycardia in patients with sarcoidosis during long term follow-up


Sarcoidosis is an important diagnostic consideration in patients with ventricular tachycardia of unknown origin. The clinical course of ventricular tachycardia as the primary presentation in patients with sarcoidosis is mostly unknown.
The aim of a study was to investigate the incidence of life-threatening ventricular tachycardia and mortality during long term follow-up in patients with sarcoidosis.

Researchers have analyzed the epidemiological features of sarcoidosis in Taiwan using the National Health Insurance Research Database from 2000 to 2004.
Patients with sarcoidosis were identified, and healthy controls without prior histories of structural heart disease were matched with a 1:1 propensity-score to the sarcoidosis group.
The risk of life-threatening ventricular tachycardia and mortality with sarcoidosis was analyzed.

A total of 2237 sarcoidosis cases were enrolled with a matching number of healthy controls, and the baseline characteristics between the two groups were similar.

After a mean follow-up of 11.4±2.15 years ( IQR: 12, 11.3-12 ), the incidence of ventricular tachycardia in the sarcoidosis group was higher than in healthy controls ( 0.94% [ 85 per 100,000 person-year ] in the sarcoidosis group, and 0.09% [ 8 per 100,000 person-year ] in healthy controls ).

After a multivariate adjustment including the sex, age, and other comorbidities, the risk of ventricular tachycardia was still higher in the sarcoidosis group ( hazard ratio, HR=2.7, 95% confidence interval: 2.82-56.9; P less than 0.001 ).

The risk of defibrillator implantations for secondary prevention, cardiovascular death, and total mortality between the groups was equivalent.

In conclusion, sarcoidosis may increase the predisposition to ventricular arrhythmias with a cumulative incidence of 0.94% during a very long term follow-up of nearly 10 years from initially diagnosing sarcoidosis. ( Xagena )

Te AL et al, Int J Cardiol 2016;228: 68-73

XagenaMedicine_2016



Indietro